+

WO1996027797A3 - Inhibiteurs de zap 70 et procedes de traitement de troubles de la transduction de signaux de zap 70 - Google Patents

Inhibiteurs de zap 70 et procedes de traitement de troubles de la transduction de signaux de zap 70 Download PDF

Info

Publication number
WO1996027797A3
WO1996027797A3 PCT/IB1996/000320 IB9600320W WO9627797A3 WO 1996027797 A3 WO1996027797 A3 WO 1996027797A3 IB 9600320 W IB9600320 W IB 9600320W WO 9627797 A3 WO9627797 A3 WO 9627797A3
Authority
WO
WIPO (PCT)
Prior art keywords
zap
signal transduction
treatment
methods
inhibitors
Prior art date
Application number
PCT/IB1996/000320
Other languages
English (en)
Other versions
WO1996027797A2 (fr
Inventor
Chaim Roifman
Original Assignee
Hsc Res Dev Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hsc Res Dev Lp filed Critical Hsc Res Dev Lp
Priority to AU51178/96A priority Critical patent/AU5117896A/en
Publication of WO1996027797A2 publication Critical patent/WO1996027797A2/fr
Publication of WO1996027797A3 publication Critical patent/WO1996027797A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Procédés de traitement, de diagnostic et de criblage pour des troubles caractérisés par une anomalie d'une voie de transduction de signaux. Ladite voie implique une interaction entre une kinase Zap 70 et un partenaire de liaison de Zap 70.
PCT/IB1996/000320 1995-03-08 1996-03-07 Inhibiteurs de zap 70 et procedes de traitement de troubles de la transduction de signaux de zap 70 WO1996027797A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU51178/96A AU5117896A (en) 1995-03-08 1996-03-07 Zap 70 inhibitors and methods for treatment of zap 70 signal transduction disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40154895A 1995-03-08 1995-03-08
US08/401,548 1995-03-08

Publications (2)

Publication Number Publication Date
WO1996027797A2 WO1996027797A2 (fr) 1996-09-12
WO1996027797A3 true WO1996027797A3 (fr) 1996-10-17

Family

ID=23588208

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1996/000320 WO1996027797A2 (fr) 1995-03-08 1996-03-07 Inhibiteurs de zap 70 et procedes de traitement de troubles de la transduction de signaux de zap 70

Country Status (2)

Country Link
AU (1) AU5117896A (fr)
WO (1) WO1996027797A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010767A2 (fr) * 1996-09-13 1998-03-19 Sugen, Inc. Utilisation de derives de la quinazoline pour la fabrication d'un medicament destine au traitement de troubles cutanes hyperproliferatifs
US6004967A (en) * 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
GB9904407D0 (en) * 1999-02-25 1999-04-21 Fluorescience Ltd Compositions and methods for monitoring the modification of engineered binding partners
US6465199B1 (en) * 1999-02-26 2002-10-15 Cyclacel, Ltd. Compositions and methods for monitoring the modification of natural binding partners

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024190A2 (fr) * 1994-03-07 1995-09-14 Sugen, Inc. Inhibiteurs de tyrosine-kinase receptrice destines a inhiber les troubles lies a la proliferation cellulaire et compositions les contenant
WO1995025118A2 (fr) * 1994-03-15 1995-09-21 Trustees Of Tufts University Inhibiteurs d'interactions des domaines sh2
WO1995026983A2 (fr) * 1994-03-31 1995-10-12 Max Planck Gesellschaft Traitement ou diagnostic de troubles caracterises par des anomalies de la transduction de signaux

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024190A2 (fr) * 1994-03-07 1995-09-14 Sugen, Inc. Inhibiteurs de tyrosine-kinase receptrice destines a inhiber les troubles lies a la proliferation cellulaire et compositions les contenant
WO1995025118A2 (fr) * 1994-03-15 1995-09-21 Trustees Of Tufts University Inhibiteurs d'interactions des domaines sh2
WO1995026983A2 (fr) * 1994-03-31 1995-10-12 Max Planck Gesellschaft Traitement ou diagnostic de troubles caracterises par des anomalies de la transduction de signaux

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHAIM. M. ROIFMAN ET AL.: "A mutation in zap-70 protein kinase results in a selective immunodeficiency", JOURNAL OF CLINICAL IMMUNOLOGY, vol. 15, no. 6, November 1995 (1995-11-01), pages 52 - 62, XP000576860 *
R. L. WANGE ET AL.: "F2(Pmp)2-TAM, anovel competitive inhibitor of the binding of ZAP-70 to the T cell antigen receptor, blocks early T cell signaling.", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 2, 13 January 1995 (1995-01-13), pages 944 - 948, XP002009592 *

Also Published As

Publication number Publication date
AU5117896A (en) 1996-09-23
WO1996027797A2 (fr) 1996-09-12

Similar Documents

Publication Publication Date Title
AU3153295A (en) Methods for treating addictive disorders
AU2684097A (en) Dietetically balanced milk product
AU5482398A (en) New substituted pyrazole derivatives for the treatment of cardiovascular disorders
AU1808595A (en) 3,8-diazabicyclo{3.2.1}octane derivatives having analgesic activity
NO951027L (no) Fremgangsmåte og apparat for elektronisk styring av akustiske signaler, samt fremgangsmåte for fremstilling av slikt apparat
AU6310696A (en) Substituted dihydrodibenz/b,f/azepines useful for treating nervous system disorders
ZA967182B (en) Asthma associated factors as targets for treating atopic allergies including asthma and related disorders.
AU3770697A (en) 2- and 2,5-substituted phenylketoenols
ZA967948B (en) Craps qualified by blackjack.
AU8102391A (en) Methods for detecting and evaluating heart disorders
AU2781997A (en) Process for the production of 1,4-butanediol, gamma-butyrolactone and tetrahydrofuran
AU6243096A (en) Multi-layer seat having different hardness and method for manufacturing the same
AU7031596A (en) Multiple cone transducer
AU5123996A (en) Bactericidal mat, process for producing the same, and use thereof
AU6123196A (en) N-aryl-1,2,4-triazolin-5-ones
WO1996027797A3 (fr) Inhibiteurs de zap 70 et procedes de traitement de troubles de la transduction de signaux de zap 70
EP2256202A3 (fr) Agent caractérisé par un signal i(kappa)b kinase ikk inductible par stimulus
AUPM456894A0 (en) Treatment for gastric disorders
ZA968210B (en) Yogurt flavour composition.
AU2233495A (en) Treatment or diagnosis of abnormal signal transduction disorders
AU6238696A (en) Cck-4, a receptor tyrosine kinase, and methods for diagnosis and treatment of cck-4 signal transduction disorders
AU7512396A (en) Plug for the cranial bone
IT1280806B1 (it) Procedimento di compressione per segnali elettroencefalografici.
AU4754496A (en) Methods for diagnosis and treatment of mdk1 signal transduction disorders
ZA929945B (en) Method of diagnosing combined cognitive/debilatory disorders.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载